Nation-wide Initiatives Fuel Breakthrough Innovations for Coronavirus and Respiratory Disorders Treatment

As governments across the world grapple with the ongoing COVID-19 (coronavirus), the India Health Fund (IHF) is inviting applications from innovators to address respiratory and airborne infections through its nation-wide search, Quest 2020. Such initiatives are encouraging effective solutions addressing respiratory disorders treatment. Thus, governments in other countries such as the U.S., Italy, and Spain can take cues from such nation-wide initiatives that can help to control COVID-19.

Since coronavirus directly affects the respiratory system of patients, governments, and laboratories have accelerated their research to minimize the severity of the virus among the affected and new patients. Ongoing R&D activities hold promising potential for innovations in the respiratory disorders treatment market. Top-tier companies in India are extending their arms to fund government initiatives in respiratory disorders treatment market. These initiatives are prioritizing the identification and diagnosis of coronavirus. There is a growing need for pre-validated solutions that can be extended for the treatment of coronavirus and other respiratory conditions.

respiratory disorders treatment market infographic

To know the scope of our report Get a Sample on Respiratory Disorders Treatment Market

Startups Innovate in Handheld Devices Capable of Delivering Information on Medication Concentrations

There is a growing demand for handheld devices capable of detecting biomarkers and molecules that deploy instant feedback on respiratory disorders. Hence, NOWA Innovations-a University of California, Irvine (UCI) startup, has introduced Unaresp™, a novel device that identifies inhaled medication concentrations and trains patients to correctly inhale medications. Such innovations are anticipated to boost the expansion of the respiratory disorders treatment market, where the market is expected to reach ~US$ 108 Bn by 2027.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the respiratory disorders treatment market are increasing their R&D capabilities to develop devices that deliver information about the quality of the patient’s exhalation and the probability of an inflamed airway. Thus, useful information on airway and breath quality is predicted to improve patient outcomes in the respiratory disorders treatment market. Companies in the market for respiratory disorders treatment are increasing efforts to fast-track the device’s approval with the FDA for future commercialization.

Lung Microbiome Deploys Individual Treatment Decisions and Disease Status

The concept of lung microbiome is acquiring popularity in the respiratory disorders treatment market. Since some of the microorganisms in lungs are uninvited gatecrashers, lung microbiome helps to provide information about the status of an individual’s disease status.

Lung microbiome is as unique as an individual’s fingerprint, thus resulting in guided individual treatment decisions that help improve patient quality of life. The novel technique also has the potential to guide companies in the respiratory disorders treatment market to develop new medicines. As such, modern laboratory techniques are being deployed to gain information about the quantity and specificity of bacteria present in the sputum samples of individuals.

Several factors such as different organisms moving into the airways as well as environmental factors determine the composition of the lung microbiome among individuals. Thus, the importance of ‘friendly’ gut bacteria is gaining widespread acceptance for respiratory disorders treatment. Healthcare providers in the market of respiratory disorders treatment can increase their efficacy in lung microbiome to identify the symptoms and perhaps decipher the slow progression of respiratory infections.

Demand for Equipment in Low-income Countries to Differentiate Asthma against Self-limiting Viral Infections

Asthma is one of the most common non-communicable disease among children, with a high prevalence worldwide. This is evident since asthma dictates the highest revenue among all diseases in the respiratory disorders treatment market, where the market estimated to progress at a healthy CAGR of ~6% during the forecast period. However, challenges concerning non-availability of equipment and medications for the treatment of asthma in low-resource settings pose as a barrier for market growth. Hence, companies in the respiratory disorders treatment market should increase their production capabilities to meet the demands of healthcare facilities in low-income countries.

Sufficient availability of equipment and necessary medications helps healthcare professionals to differentiate between common respiratory conditions such as pneumonia and asthma versus self-limiting viral infections. Apart from this, there is a growing awareness about non-pharmacological interventions that are underutilized, but can ease symptoms of patients requiring respiratory disorders treatment.

respiratory disorders treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Given the current public health exigencies amidst the COVID-19 crisis, nation-wide search programs inviting innovators to showcase pre-validated solutions are helping to control the virus. The concept of lung microbiome is acquiring widespread acceptance in the respiratory disorders treatment market to demonstrate how microbiomes are associated with other disorders such as cancer, stroke, and obesity.

Non-pharmacological interventions such as cognitive behavioral techniques are helping to improve the quality of life of chronic obstructive pulmonary disease (COPD) patients. However, there is a need to educate asthma and COPD patients on how to take their medications, which is one of the biggest issues that companies face. Hence, companies should gain expertise in devices that train patients on how to properly inhale their medications.

Respiratory Disorders Treatment Market: Overview

  • According to Transparency Market Research’s latest report on the respiratory disorders treatment market for the historical period 2017–2018 and forecast period 2019–2027, increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders, entry of new players, and rise in access to healthcare are projected to drive the global respiratory disorders treatment market
  • According to the report, the global respiratory disorders treatment market was valued at ~US$ 64 Bn in 2018 and is anticipated to expand at a CAGR of ~6% from 2019 to 2027

Rise in Prevalence of Respiratory Disorders and Surge in Adoption of Combination Therapy: Key Drivers

  • Rise in focus on smart or digital inhalers for administration of asthma or COPD drugs drives the global respiratory disorders treatment market
  • Combination therapy includes LAMA-ICS and LABA-ICS. Adoption of combination therapy is increasing, as these are more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.
  • Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory disorders such as asthma and COPD
  • According to the WHO, prevalence of allergic diseases in the developed world has increased significantly in the past 50 years. According to the World Health Organization (White Book on Allergy 2011–2012), allergic rhinitis affects around 30% of the global population.
  • According to the Global Burden of Disease Study, 251 million COPD cases were reported in 2016 and 3.17 million deaths were caused due to the disease in 2015. Therefore, there is a need of early diagnosis and treatment of the disease.

Focus on Geographic Expansion

  • Most respiratory disorder-related deaths occur in low- and lower-middle income countries. High prevalence of respiratory diseases, increase in availability of quality health care services, and growth of the pharmaceutical industry in emerging economies across the globe are creating lucrative opportunities in the respiratory disorders treatment market in these countries.
  • China and Japan are likely to present significant opportunities in the market due to the presence of leading players. In November 2015, F. Hoffmann-La Roche Ltd. opened its new pharmaceutical manufacturing center in Shanghai, China.
  • Rapid adoption of emerging technologies and surge in innovation are the other important aspects that present opportunities in the respiratory disorders treatment market. Moreover, rapid growth and development of the pharmaceutical industry, rise in availability of branded drugs, and increase of burden of respiratory diseases augment the respiratory disorders treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Respiratory Disorders Treatment Market

  • Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. Patent expiry hampers the revenue generated from the sale of branded drugs and can affect the market share of a company.
  • A few players in the respiratory disorders treatment market face the threat of patient expiry, which increases the availability of generic versions of drugs and create pricing pressure on the manufacturers
  • For instance, AstraZeneca’s Symbicort Turbuhaler went off patent in Europe in 2019, while patents of GlaxoSmithKline plc’s Qvar, Singulair, and Diskus have expired. This is likely to lead to dramatic losses in sales, thereby affecting positions of the companies in the global respiratory disorders treatment market.

Respiratory Disorders Treatment Market: Competition Landscape

  • This report profiles major players in the global respiratory disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global respiratory disorders treatment market is less fragmented, with the presence of large number of international as well as regional players
  • Leading players operating in the global respiratory disorders treatment market are 
    • Mylan N.V
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Sanofi
    • Sunovion Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries
    • CHIESI Farmaceutici S.p.A.
    • Cipla
    • Vertex Pharmaceuticals Incorporated. 
  • These players account for over 50% share of the global market.

Respiratory Disorders Treatment Market: Key Developments

  • Key players in the global respiratory disorders treatment market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the global respiratory disorders treatment market. A few expansion strategies adopted by players operating in the respiratory disorders treatment market are:
    • In September 2019, GlaxoSmithKline plc announced the U.S. Food and Drug Administration (FDA) approval for its biologics Nucala (mepolizumab) for the treatment of severe eosinophilic asthma in children aged between 6 and 11. This approval has extended the add-on treatment for severe eosinophilic asthma in the U.S. for patients between 6 and 11.
    • In July 2019, AstraZeneca received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to use Fasenra (benralizumab) in pre-filled, single-use auto-injector (the Fasenra pen). This enabled doctors to treat several patients suffering from severe eosinophilic asthma with biologics.
    • In April 2019, Boehringer Ingelheim International GmbH invested EUR 105 Mn to expand its production sites in Dortmund and Ingelheim in Germany for development of respiratory pipeline products. This investment and expansion would boost the production capacity of next-gen inhaler Respimat in Europe.
  • The report on the global respiratory disorders treatment market discussed individual strategies, followed by company profiles of manufacturers of respiratory disorders treatment products. The competitive landscape section has been included in the respiratory disorders treatment market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global respiratory disorders treatment market.

Respiratory Disorders Treatment Market - Segmentation

Disease

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Lung Cancer

Respiratory Tract Infection

Allergic Rhinitis

Cystic Fibrosis (CF)

Others

Drug Class

Bronchodilators

Corticosteroids

Combination Drugs

Antibiotics

Target Therapy

Immunotherapy

CFTR

Others

Route of Administration

Oral

Nasal

Injectable

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

The global respiratory disorders treatment market was worth US$ 65 Bn and is projected to reach a value of US$ 108 Bn by the end of 2026

Respiratory disorders treatment market is anticipated to grow at a CAGR of 6% during the forecast period

North America accounted for a major share of the global respiratory disorders treatment market

Respiratory disorders treatment market is driven by increase in incidence of respiratory disorders, surge in supportive care products to meet the rise in demand for treatment of respiratory disorders and entry of new players

Key players in the global respiratory disorders treatment market include Mylan N.V, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Sanofi, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A., Cipla, Vertex Pharmaceuticals Incorporated

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Disorders Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Route of Administration Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Respiratory Disorders Treatment Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Bn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Health Care Industry Overview

    5.2. Health Care Industry Overview

    5.3. Pipeline Analysis (asthma, lung cancer, COPD)

    5.4. Disease Prevalence Rate in Key Countries

    5.5. Disease Management

    5.6. Key Market Events

    5.7. Regulatory Scenario

    5.8. Reimbursement Scenario

    5.9. Technological Advancements

6. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Respiratory Disorders Treatment Market Value Forecast, by Drug Class, 2017–2027

        6.2.1. Bronchodilators

        6.2.2. Corticosteroids

        6.2.3. Combination Drugs

        6.2.4. Antibiotics

        6.2.5. Target Therapy

        6.2.6. Immunotherapy

        6.2.7. CFTR

    6.3. Others Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class

7. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Disease

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Respiratory Disorders Treatment Market Value Forecast, by Disease, 2017–2027

        7.2.1. Asthma

        7.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        7.2.3. Lung Cancer

        7.2.4. Respiratory Tract Infection

        7.2.5. Allergic Rhinitis

        7.2.6. Cystic Fibrosis (CF)

        7.2.7. Others 

    7.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease

8. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Route of Administration 

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Respiratory Disorders Treatment Market Value Forecast, by Route of Administration, 2017–2027

        8.2.1. Oral

        8.2.2. Nasal

        8.2.3. Injectable 

    8.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration 

9. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Distribution Channel 

    9.1. Introduction & Definition

        9.1.1. Key Findings / Developments

    9.2. Global Respiratory Disorders Treatment Market Value Forecast, by Distribution Channel, 2017–2027

        9.2.1. Hospital Pharmacies

        9.2.2. Retail Pharmacies

        9.2.3. Online Pharmacies

    9.3. Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel

10. Global Respiratory Disorders Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Respiratory Disorders Treatment Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Region

11. North America Respiratory Disorders Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

        11.2.1. Bronchodilators

        11.2.2. Corticosteroids

        11.2.3. Combination Drugs

        11.2.4. Antibiotics

        11.2.5. Target Therapy

        11.2.6. Immunotherapy

        11.2.7. CFTR

    11.3. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

        11.3.1. Asthma

        11.3.2. Chronic Obstructive Pulmonary Disease (COPD)

        11.3.3. Lung Cancer

        11.3.4. Respiratory Tract Infection

        11.3.5. Allergic Rhinitis

        11.3.6. Cystic Fibrosis (CF)

        11.3.7. Others 

    11.4. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

        11.4.1. Oral

        11.4.2. Nasal

        11.4.3. Injectable 

    11.5. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Respiratory Disorders Treatment Market Attractiveness Analysis 

        11.7.1. By Drug Class

        11.7.2. By Disease

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Respiratory Disorders Treatment Market Analysis and Forecast

    12.1. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

        12.1.1. Bronchodilators

        12.1.2. Corticosteroids

        12.1.3. Combination Drugs

        12.1.4. Antibiotics

        12.1.5. Target Therapy

        12.1.6. Immunotherapy

        12.1.7. CFTR

    12.2. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

        12.2.1. Asthma

        12.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        12.2.3. Lung Cancer

        12.2.4. Respiratory Tract Infection

        12.2.5. Allergic Rhinitis

        12.2.6. Cystic Fibrosis (CF)

        12.2.7. Others 

    12.3. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

        12.3.1. Oral

        12.3.2. Nasal

        12.3.3. Injectable 

    12.4. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies 

    12.5. Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. Germany

        12.5.2. U.K.

        12.5.3. France

        12.5.4. Spain

        12.5.5. Italy

        12.5.6. Rest of Europe 

    12.6. Europe Respiratory Disorders Treatment Market Attractiveness Analysis 

        12.6.1. By Drug Class

        12.6.2. By Disease

        12.6.3. By Route of Administration

        12.6.4. By Distribution Channel

        12.6.5. By Country/Sub-region

13. Asia Pacific Respiratory Disorders Treatment Market Analysis and Forecast

    13.1. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

        13.1.1. Bronchodilators

        13.1.2. Corticosteroids

        13.1.3. Combination Drugs

        13.1.4. Antibiotics

        13.1.5. Target Therapy

        13.1.6. Immunotherapy

        13.1.7. CFTR

    13.2. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

        13.2.1. Asthma

        13.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        13.2.3. Lung Cancer

        13.2.4. Respiratory Tract Infection

        13.2.5. Allergic Rhinitis

        13.2.6. Cystic Fibrosis (CF)

        13.2.7. Others 

    13.3. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

        13.3.1. Oral

        13.3.2. Nasal

        13.3.3. Injectable 

    13.4. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies 

    13.5. Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. China

        13.5.2. Japan

        13.5.3. India

        13.5.4. Australia & New Zealand

        13.5.5. Rest of Asia Pacific 

    13.6. Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis 

        13.6.1. By Drug Class

        13.6.2. By Disease

        13.6.3. By Route of Administration

        13.6.4. By Distribution Channel

        13.6.5. By Country/Sub-region

14. Latin America Respiratory Disorders Treatment Market Analysis and Forecast

    14.1. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

        14.1.1. Bronchodilators

        14.1.2. Corticosteroids

        14.1.3. Combination Drugs

        14.1.4. Antibiotics

        14.1.5. Target Therapy

        14.1.6. Immunotherapy

        14.1.7. CFTR

    14.2. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

        14.2.1. Asthma

        14.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        14.2.3. Lung Cancer

        14.2.4. Respiratory Tract Infection

        14.2.5. Allergic Rhinitis

        14.2.6. Cystic Fibrosis (CF)

        14.2.7. Others 

    14.3. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

        14.3.1. Oral

        14.3.2. Nasal

        14.3.3. Injectable 

    14.4. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies 

    14.5. Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. Brazil

        14.5.2. Mexico

        14.5.3. Rest of Latin America Latin America 

    14.6. Latin America Respiratory Disorders Treatment Market Attractiveness Analysis 

        14.6.1. By Drug Class

        14.6.2. By Disease

        14.6.3. By Route of Administration

        14.6.4. By Distribution Channel

        14.6.5. By Country/Sub-region

15. Middle East & Africa Respiratory Disorders Treatment Market Analysis and Forecast

    15.1. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

        15.1.1. Bronchodilators

        15.1.2. Corticosteroids

        15.1.3. Combination Drugs

        15.1.4. Antibiotics

        15.1.5. Target Therapy

        15.1.6. Immunotherapy

        15.1.7. CFTR

    15.2. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

        15.2.1. Asthma

        15.2.2. Chronic Obstructive Pulmonary Disease (COPD)

        15.2.3. Lung Cancer

        15.2.4. Respiratory Tract Infection

        15.2.5. Allergic Rhinitis

        15.2.6. Cystic Fibrosis (CF)

        15.2.7. Others 

    15.3. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

        15.3.1. Oral

        15.3.2. Nasal

        15.3.3. Injectable 

    15.4. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

        15.4.1. Hospital Pharmacies

        15.4.2. Retail Pharmacies

        15.4.3. Online Pharmacies 

    15.5. Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

        15.5.1. GCC Countries

        15.5.2. South Africa

        15.5.3. Rest of Middle East & Africa 

    15.6. Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis 

        15.6.1. By Drug Class

        15.6.2. By Disease

        15.6.3. By Route of Administration

        15.6.4. By Distribution Channel

        15.6.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by Tier and Size of companies)

    16.2. Market Share / Position Analysis, by Company, 2018

    16.3. Competitive Business Strategies

    16.4. Company Profiles

        16.4.1. GlaxoSmithKline plc

            16.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.1.2. Growth Strategies

            16.4.1.3. SWOT Analysis

        16.4.2. Merck & Co., Inc.

            16.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.2.2. Growth Strategies

            16.4.2.3. SWOT Analysis

        16.4.3. AstraZeneca

            16.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.3.2. Growth Strategies

            16.4.3.3. SWOT Analysis

        16.4.4. Boehringer Ingelheim International GmbH

            16.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.4.2. Growth Strategies

            16.4.4.3. SWOT Analysis

        16.4.5. Novartis AG

            16.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.5.2. Growth Strategies

            16.4.5.3. SWOT Analysis

        16.4.6. F. Hoffmann-La Roche Ltd. 

            16.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.6.2. Growth Strategies

            16.4.6.3. SWOT Analysis 

        16.4.7. Teva Pharmaceutical Industries Ltd.

            16.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.7.2. Growth Strategies

            16.4.7.3. SWOT Analysis

        16.4.8. Sanofi

            16.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.8.2. Growth Strategies

            16.4.8.3. SWOT Analysis

        16.4.9. Cipla, Inc.

            16.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.9.2. Growth Strategies

            16.4.9.3. SWOT Analysis

        16.4.10. Sun Pharmaceutical Industries Ltd. 

            16.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.10.2. Growth Strategies

            16.4.10.3. SWOT Analysis 

        16.4.11. Mylan N.V.

            16.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.11.2. Growth Strategies

            16.4.11.3. SWOT Analysis

        16.4.12. Takeda Pharmaceutical Company Limited

            16.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.12.2. Growth Strategies

            16.4.12.3. SWOT Analysis

        16.4.13. CHIESI Farmaceutici S.p.A.

            16.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.13.2. Growth Strategies

            16.4.13.3. SWOT Analysis

        16.4.14. Orion Corporation

            16.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.14.2. Growth Strategies

            16.4.14.3. SWOT Analysis

        16.4.15. Vertex Pharmaceutical

            16.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.15.2. Growth Strategies

            16.4.15.3. SWOT Analysis

List of Tables

Table 01: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

Table 02: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

Table 03: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

Table 04: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Region, 2017–2027

Table 06: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2027

Table 07: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

Table 08: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

Table 09: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

Table 10: North America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

Table 11: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

Table 13: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

Table 14: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

Table 15: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

Table 18: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

Table 19: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

Table 20: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

Table 21: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

Table 23: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

Table 24: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

Table 25: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

Table 26: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2027

Table 27: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Drug Class, 2017–2027

Table 28: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Disease, 2017–2027

Table 29: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017–2027

Table 30: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Respiratory Disorders Treatment Market Value (US$ Bn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Respiratory Disorders Treatment Market Value (US$ Bn) Forecast, 2017–2027

Figure 03: Global Respiratory Disorders Treatment Market Value Share (%), by Drug Class, 2018

Figure 04: Global Respiratory Disorders Treatment Market Value Share (%), by Disease, 2018

Figure 05: Global Respiratory Disorders Treatment Market Value Share (%), by Route of Administration, 2018

Figure 06: Global Respiratory Disorders Treatment Market Value Share (%), by End-user, 2018

Figure 07: Global Respiratory Disorders Treatment Market Value Share (%), by Region, 2018

Figure 08: Global Respiratory Disorders Treatment Market Value Share (%), by Drug Class, 2018 and 2027

Figure 09: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 10: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Bronchodilators, 2017–2027

Figure 11: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 12: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Combination Drugs, 2017–2027

Figure 13: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Antibiotics, 2017–2027

Figure 14: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Target Therapy, 2017–2027

Figure 15: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Immunotherapy, 2017–2027

Figure 16: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by CFTR, 2017–2027

Figure 17: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 18: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027

Figure 19: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027

Figure 20: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Asthma, 2017–2027

Figure 21: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Chronic Obstructive Pulmonary Disease (COPD), 2017–2027

Figure 22: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Lung Cancer, 2017–2027

Figure 23: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Respiratory Tract Infection, 2017–2027

Figure 24: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Allergic Rhinitis, 2017–2027

Figure 25: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Cystic Fibrosis (CF), 2017–2027

Figure 26: Global Respiratory Disorders Treatment Market Revenue (US$ Bn), by Others, 2017–2027

Figure 27: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 28: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 29: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 30: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Nasal, 2017–2027

Figure 31: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Injectable, 2017–2027

Figure 32: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 33: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 34: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 35: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 36: Global Respiratory Disorders Treatment Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 37: Global Respiratory Disorders Treatment Market Value Share (%) Analysis, by Region, 2018 and 2027

Figure 38: Global Respiratory Disorders Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 39: North America Respiratory Disorders Treatment Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 40: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country, 2018 and 2027

Figure 41: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Country, 2019–2027

Figure 42: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

Figure 43: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 44: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027

Figure 45: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027

Figure 46: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 47: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 48: North America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 49: North America Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 50: Europe Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 51: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country/Sub-Region, 2018 and 2027

Figure 52: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 53: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

Figure 54: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 55: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027

Figure 56: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027

Figure 57: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 58: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 59: Europe Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 60: Europe Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 61: Asia Pacific Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 62: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2018 and 2027

Figure 63: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 64: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

Figure 65: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 66: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027

Figure 67: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027

Figure 68: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 69: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 70: Asia Pacific Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 71: Asia Pacific Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 72: Latin America Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 73: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2018 and 2027

Figure 74: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 75: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

Figure 76: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 77: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027

Figure 78: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027

Figure 79: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 80: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 81: Latin America Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 82: Latin America Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 83: Middle East & Africa Respiratory Disorders Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 84: Middle East & Africa Respiratory Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 85: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 86: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

Figure 87: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 88: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Disease, 2018 and 2027

Figure 89: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Disease, 2019–2027

Figure 90: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 91: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 92: Middle East & Africa Respiratory Disorders Treatment Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 93: Middle East & Africa Respiratory Disorders Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Respiratory Disorders Treatment Market